Danish pharmaceutical giant Novo Nordisk (NVO) faced significant market pressure in mid-October, with shares tumbling 5.6% in their worst single-day performance in nearly a month. The sell-off was triggered by President Donald Trump’s pledge to slash prices for weight-loss drugs, directly targeting Novo Nordisk’s blockbuster product Ozempic. Trump vowed to bring the cost “down to $150” – a dramatic 85% reduction from its current out-of-pocket monthly price of approximately $1,000.
The political pressure comes amid an already challenging period for the drugmaker. While Novo Nordisk has proactively cut some list prices by up to 50% to improve accessibility, Trump’s proposal represents a far more aggressive target. This external pressure compounds existing concerns, including recent clinical setbacks, disappointing earnings, and market share loss for Wegovy to rival Eli Lilly’s Zepbound.
Despite these headwinds, a compelling investment thesis is emerging around Novo Nordisk. The stock’s recent weakness has created an attractive entry point, with its price-to-earnings ratio of 14.6 sitting well below its five-year average of 31.3. Similarly, its price-to-sales ratio of 5.2 compares favorably to its historical average of 10.6.
Several factors support the long-term investment case:
Resilient Market Position: While Medicare price negotiations could affect about 18% of the U.S. population, the underlying demand story remains robust. Diabetes and obesity affect massive patient populations – approximately 38 million Americans have diabetes, while 40% of adults struggle with obesity.
Pipeline Innovation: Novo Nordisk is advancing multiple promising developments, including an oral version of Wegovy that expects FDA approval well ahead of Eli Lilly’s competing candidate. The company is also investigating Ozempic’s potential to slow cognitive decline in Alzheimer’s patients and developing a third weight-loss drug.
Strong Financial Performance: The company’s fundamental business remains healthy, with first-half revenue growing 16% year-over-year, operating profit up 25%, and net profit increasing 22%.
Analysts note that Novo Nordisk has successfully navigated pricing pressures before, notably with its insulin products in 2023. The company appears to be executing a “staged defense strategy” for its semaglutide franchise, maximizing returns during patent protection through 2031 while transitioning to next-generation products.
The recent stock decline – shares are down 52.5% over the past year – contrasts sharply with the company’s solid operational performance and the massive addressable market for GLP-1 drugs. With global sales for semaglutide products projected to surpass $35 billion by 2025, current valuations may significantly undervalue Novo Nordisk’s long-term growth potential in the rapidly expanding metabolic disease treatment market.
